Cargando…

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing of circulating cell-free tumor DNA (ctDNA) in patients with ACC, to characterize the genomic landscape of alteration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazha, Bassel, Zhuang, Tony Z, Dada, Hiba I, Drusbosky, Leylah M, Brown, Jacqueline T, Ravindranathan, Deepak, Carthon, Bradley C, Kucuk, Omer, Goldman, Jamie, Master, Viraj A, Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Genitourinary Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177103/ https://www.ncbi.nlm.nih.gov/pubmed/35462410 http://dx.doi.org/10.1093/oncolo/oyac061

Ejemplares similares

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Inflammatory Markers in Cancer Immunotherapy
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
por: Bergerot, Cristiane Decat, et al.
Publicado: (2023)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Myxoid Adrenocortical Adenoma: Magnetic Resonance Imaging and Pathology Correlation
por: Kim, Tae Un, et al.
Publicado: (2014)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Rare presentation of inflammatory myofibroblastic tumor in the kidney
por: Abduljawad, Hiba, et al.
Publicado: (2020)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report
por: Evans, Jaden D., et al.
Publicado: (2017)

Salvage image guided radiation therapy to the prostate after cryotherapy failure
por: Hopper, Austin B., et al.
Publicado: (2017)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
por: Vargas, Carlos E., et al.
Publicado: (2018)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
por: Schad, Michael D., et al.
Publicado: (2019)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States
por: Scherzer, Nickolas D., et al.
Publicado: (2019)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Pathologic Complete Response After Chemoradiation of a Massive Primary Urethral Carcinoma
por: Singh, Tanmay, et al.
Publicado: (2019)

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking
por: Chaurasia, Avinash R., et al.
Publicado: (2018)

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
por: Toesca, Diego A.S., et al.
Publicado: (2018)

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer
por: Castro, Elena, et al.
Publicado: (2016)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jugmrc1s9vtcicsq1m1r13dq9d